Physician profile
Rena Simon
NPI 1558947994
$3,857.30
in general payments reported to CMS, 2019-2025
23 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,293 · 2024: $1,496 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,347.33 |
| Education | $509.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $887.41 | 2023-2025 | Ilumya, Odomzo, Blu-U |
| Lilly USA, LLC | $461.13 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Abbvie INC. | $447.76 | 2023-2025 | |
| Genzyme Corporation | $432.11 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $371.65 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $269.29 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $220.52 | 2023-2025 | |
| Ucb, INC. | $186.13 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $105.95 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $74.73 | 2023-2024 | Opzelura |
| Galderma Laboratories, L.P. | $61.13 | 2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.28 | 2023-2024 | Spevigo |
| Pfizer INC. | $49.38 | 2025 | |
| Leo Pharma INC. | $41.47 | 2023-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $29.84 | 2024 | Erivedge |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $25.71 | 2025 | Seysara |
| Mallinckrodt Hospital Products INC. | $25.58 | 2024 | Acthar |
| Organon LLC | $23.98 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $21.41 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $20.73 | 2024 | Sotyktu |
| Verrica Pharmaceuticals INC. | $19.07 | 2024 | Ycanth |
| Biofrontera INC. | $18.69 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $13.35 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.